Thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels exhibit a large interindividual variability in which genetic control seems to play a major role. However, recent reports have questioned the association between TAFI concentration and genotype, suggesting that variable antibody reactivity towards TAFI isoforms, particularly the Thr325Ile polymorphism (1040C/T), may lead to artefacts in TAFI antigen levels. In order to compare assay outcome we determined plasma TAFI levels in 92 healthy individuals, using an enzyme-linked immunosorbent assay (ELISA) (commercial antibodies), an electroimmunoassay (in-house antibodies) and a commercial chromogenic assay (Actichrome® TAFI). Each individual was genotyped for the -438A/G and 1040C/T polymorphisms in the TAFI gene. TAFI levels were significantly associated with genotype in both antigen and chromogenic assays. All assays displayed significant correlations with each other. Linear regression and Bland-Altman agreement analysis in the genotype subgroups showed that neither the genotype nor the concentration affected the relationship between the Actichrome® TAFI and the electroimmunoassay. In contrast, the ELISA/Actichrome® TAFI and the ELISA/electroimmunoassay relationships were concentration- and genotype-dependent. Our results demonstrate that artefacts may arise when measuring TAFI antigen levels by ELISA. Nevertheless, the electroimmunoassay and the Actichrome® TAFI assay support a genotype-related variation of TAFI concentration.

, , , ,,
British Journal of Haematology
Department of Hematology

Guimarães, A.H.C, van Tilburg, N.H, Vos, H.L, Bertina, R.M, & Rijken, D.C. (2004). Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: Comparison of different assays. British Journal of Haematology, 124(5), 659–665. doi:10.1111/j.1365-2141.2004.04824.x